Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Hu antibodies“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Hu antibodies" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Hu antibodies"
Monstad, S. E., L. Drivsholm, A. Storstein, J. H. Aarseth, M. Haugen, B. Lang, A. Vincent und C. A. Vedeler. „Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer“. Journal of Clinical Oncology 22, Nr. 5 (01.03.2004): 795–800. http://dx.doi.org/10.1200/jco.2004.01.028.
Der volle Inhalt der QuelleVerschuuren, J., A. Twijnstra, M. De Baets, F. Thunnissen, J. Dalmau und P. van Breda Vriesman. „Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma“. Neurology 44, Nr. 8 (01.08.1994): 1551. http://dx.doi.org/10.1212/wnl.44.8.1551.
Der volle Inhalt der QuelleManley, Geoffrey T., Peter Sillevis Smitt, Josep Dalmau und Jerome B. Posner. „Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites“. Annals of Neurology 38, Nr. 1 (Juli 1995): 102–10. http://dx.doi.org/10.1002/ana.410380117.
Der volle Inhalt der QuelleTOTLAND, C., J. AARSETH und C. VEDELER. „Hu and Yo antibodies have heterogeneous avidity“. Journal of Neuroimmunology 185, Nr. 1-2 (April 2007): 162–67. http://dx.doi.org/10.1016/j.jneuroim.2007.01.016.
Der volle Inhalt der QuelleGreenlee, John E., John D. Steffens, Susan A. Clawson, Kenneth Hill und Josep Dalmau. „Anti-Hu antibodies in Merkel cell carcinoma“. Annals of Neurology 52, Nr. 1 (21.06.2002): 111–15. http://dx.doi.org/10.1002/ana.10225.
Der volle Inhalt der QuelleFarina, Antonio, Macarena Villagrán-García, Nicolás Lundahl Ciano-Petersen, Alberto Vogrig, Sergio Muñiz-Castrillo, Luc Taillandier, Maud Michaud et al. „Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors“. Neurology - Neuroimmunology Neuroinflammation 10, Nr. 1 (29.11.2022): e200058. http://dx.doi.org/10.1212/nxi.0000000000200058.
Der volle Inhalt der QuelleZiller, MG, EL Göttke, M. Bambonye und R. Dalfen. „P.039 New association of anti-Hu positive limbic encephalitis and sensory ganglionopathy with small cell gastric tumour“. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43, S2 (Juni 2016): S30. http://dx.doi.org/10.1017/cjn.2016.143.
Der volle Inhalt der QuelleWilliams, S. S., T. Umemoto, H. Kida, E. A. Repasky und R. B. Bankert. „Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.“ Journal of Immunology 149, Nr. 8 (15.10.1992): 2830–36. http://dx.doi.org/10.4049/jimmunol.149.8.2830.
Der volle Inhalt der QuelleMukherjee, Jean, Kerry Chios, Dianne Fishwild, Deborah Hudson, Susan O'Donnell, Stephen M. Rich, Arthur Donohue-Rolfe und Saul Tzipori. „Production and Characterization of Protective Human Antibodies against Shiga Toxin 1“. Infection and Immunity 70, Nr. 10 (Oktober 2002): 5896–99. http://dx.doi.org/10.1128/iai.70.10.5896-5899.2002.
Der volle Inhalt der QuelleCamdessanché, Jean‐Philippe, Jean‐Christophe Antoine, Jérôme Honnorat, Christophe Vial, Philippe Petiot, Philippe Convers und Daniel Michel. „Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies“. Brain 125, Nr. 1 (01.01.2002): 166–75. http://dx.doi.org/10.1093/brain/awf006.
Der volle Inhalt der QuelleDissertationen zum Thema "Hu antibodies"
Villagrán-García, Macarena. „Clinical-immunological characterization and immune tolerance breakdown in paraneoplastic neurological syndromes associated with Hu antibodies“. Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10259.
Der volle Inhalt der QuelleHu antibodies, the most common in paraneoplastic neurological syndromes (PNS), strongly indicate small-cell lung cancer (SCLC). The clinical spectrum of Hu-PNS is diverse, most patients develop multifocal central, peripheral, and/or autonomic nervous system dysfunction. Despite extensive research, questions remain, namely regarding the immunological basis of clinical heterogeneity and why only a minority of SCLC patients develop Hu-PNS. Our PhD project aims to phenotype Hu-PNS patients, explore the immunogenetics and humoral responses underlying neurological phenotypes, and the genomic and transcriptomic features of their SCLC. First, we described 466 Hu-PNS patients. Hierarchical clustering identified three groups: patients with central nervous system (CNS) involvement; isolated neuropathy; and mixed CNS/peripheral phenotypes. Overall survival was similar across groups, primarily determined by cancer, but dysautonomia, present in 26% of patients, significantly influenced neurological mortality. Prominent CNS dysfunction led to fatal cardiovascular dysautonomia or central hypoventilation, while peripheral involvement was associated with gastrointestinal or secretomotor alterations, without increased mortality risk. We also characterized patients who developed neurological syndromes with Hu antibodies after immune checkpoint inhibitor (ICI) treatment. These patients were clinically indistinguishable from spontaneous cases and shared a strong association with SCLC, suggesting ICIs may induce Hu-PNS. Second, we immunologically investigated neurological phenotypes using two approaches. HLA genotyping of 100 patients confirmed an association with the DR3~DQ2 haplotype, particularly in patients with sensory neuropathy, and absent in those with only CNS involvement. Phage immunoprecipitation sequencing was used to evaluate Hu antibody epitope reactivity and other autoantibodies in serum and/or CSF of 210 patients. We found no direct clinical association with the Hu dominant epitope, but epitope reactivity differed between serum and CSF in 75% of patients with paired samples. This variation correlated with sample timing and phenotype: CSF from patients with differing serum/CSF epitopes was collected later after PNS onset, while patients with serum/CSF consistent epitope reactivity always had CNS phenotypes. In addition, we identified reactivities to other proteins, some more specific to serum or CSF, and a subset linked to specific phenotypes. Third, we examined SCLC molecular features of Hu-, GABAbR-PNS and control patients. Next-generation sequencing, copy number variation analysis, and bulk-RNA sequencing revealed no mutations, gains, deletions, or overexpression in the Hu gene family of Hu-PNS SCLC. However, a distinct transcriptomic profile with upregulated genes largely related to immune system processes characterized these tumors. We also identified specific genes upregulated in the SCLC of patients with sensory neuropathy, some of which were linked to axonogenesis and neuropathy development. Our findings suggest multiple factors contribute to Hu-PNS clinical variability, particularly a broad range of additional autoantigens. These may be partly driven by gene expression patterns in SCLC, as some upregulated genes in patients with sensory neuropathy were linked to axonogenesis. Genetic predisposition may also favor specific phenotypes, as the DR3~DQ2 haplotype was associated with sensory neuropathy. Compartmentalization within the nervous system could further contribute, as most patients targeted different Hu epitopes in serum and CSF, and some autoantigens were more specific to CSF. Finally, Hu genes alterations in SCLC are unlikely causes of neoantigenicity, while a distinct immune-related gene profile and ICIs could contribute to immune tolerance breakdown. This work advances understanding of Hu-PNS complexity and paves the way for further studies into the immunological and molecular drivers of paraneoplastic immunity
Bücher zum Thema "Hu antibodies"
McKeon, Andrew. Autoimmune Encephalitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0097.
Der volle Inhalt der QuelleHodgkiss, Andrew. Psychiatric consequences of particular cancers. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0004.
Der volle Inhalt der QuelleBuchteile zum Thema "Hu antibodies"
Miller, Aaron E., Tracy M. DeAngelis, Michelle Fabian und Ilana Katz Sand. „On the Right Tract“. In Neuroimmunology, 109–12. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190693190.003.0020.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Hu antibodies"
Yagnik, Deepti, Josephine Chan, Ben McGettigan, Andrew Laycock und Allycia MacDonald. „3121 New onset refractory epilepsy (NORSE) secondary to anti-glutamic acid decarboxylase (anti-GAD) and anti-Hu antibodies related paraneoplastic encephalitis from lymphocyte-rich thymoma“. In ANZAN Annual Scientific Meeting 2024 Abstracts, A39.3—A40. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/bmjno-2024-anzan.110.
Der volle Inhalt der QuelleLi, Xi, Kara L. Maki und Michael J. Schertzer. „A Low Cost Fabrication Method for Electrowetting Assisted Desiccation of Colloidal Droplets“. In ASME 2017 Fluids Engineering Division Summer Meeting. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/fedsm2017-69465.
Der volle Inhalt der Quelle